CORRIGENDUM

Integrins in cancer: biological implications and therapeutic opportunities

Jay S. Desgrosellier & David A. Cheresh

Nature Reviews Cancer **10**, 9–22 (2010)

On page 17 of this article, in the section *Targeting αvβ3 and αvβ5* the sentence at the start of the second paragraph that reads "Cilengitide is an inhibitor of both αvβ3 and αvβ5 integrins, and it was selected in our laboratory by screening a library of cyclic RGD peptides in a cell-free receptor assay for their capacity to inhibit integrins αvβ3 and αvβ5 but not αIIbβ3 (REF. 130)." was incorrectly phrased. The corrected sentence with additional references is given below.
"Cilengitide is an inhibitor of both αvβ3 and αvβ5 integrins. We had shown that αvβ3 and αvβ5 integrins were important regulators of angiogenesis and tumour growth[49,51,191,192] and developed a cell-free receptor assay to select for antagonists of integrins αvβ3 and αvβ5 that did not effect integrin αIIbβ3 (REF. 130). This assay was used to screen a library of integrin binding cyclic RGD peptides designed and synthesized by H. Kessler and colleagues for αvβ3 activity and selectivity[193–195] from which cilengitide was developed[196]".

191. Cheresh, D. A. Human endothelial cells synthesize and express an Arg Gly Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. *Proc. Natl. Acad. Sci. USA* **84**, 6471–6475 (1987).
192. Brooks, P. C. *et al.* Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. *Cell* **79**, 1157–1164 (1994).
193. Aumailley, M. *et al.* Arg Gly Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. *FEBS Lett.* **291**, 50–54 (1991).
194. Gurrath, M. *et al.*, Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides; *Eur. J. Biochem.*, **210**, 911–921 (1992).
195. Pfaff, M. *et al.*, Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by αIIbβ3, αVβ3 and α5β1 Integrins. *J. Biol. Chem.*, **269**, 20233–20238 (1994).
196. Dechantsreiter, M. A. *et al. N*-Methylated cyclic RGD peptides as highly active and selective $\alpha_v\beta_3$ integrin antagonists. *J. Med. Chem.* **42**, 3033–3040 (1999).